MedTrace Logo

GABA Pathways in Autism Spectrum Disorder (ASD)

NCT03678129 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2025-08-26

No results posted yet for this study

Summary

This study investigates the brain response to a single acute dose of a GABAa receptor acting drug (Benzodiazepine or positive allosteric modulator) compared to a single dose of placebo in adults with and without autism spectrum disorder.

Conditions

Interventions

DRUG

AZD7325_10

Single oral dose (10mg)

DRUG

AZD7325_20

Single oral dose (20mg)

DRUG

Placebo

Single oral dose placebo (capsule)

DRUG

Clobazam

Single dose (5mg)

Sponsors & Collaborators

Principal Investigators

  • Grainne McAlonan, PhD · King's College London, UK

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-07
Primary Completion
2025-06-27
Completion
2025-06-27

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03678129 on ClinicalTrials.gov